These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
240 related items for PubMed ID: 17322412
1. Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation. Bulhak A, Roy J, Hedin U, Sjöquist PO, Pernow J. Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H3158-63. PubMed ID: 17322412 [Abstract] [Full Text] [Related]
2. Rosuvastatin given during reperfusion decreases infarct size and inhibits matrix metalloproteinase-2 activity in normocholesterolemic and hypercholesterolemic rabbits. D'Annunzio V, Donato M, Erni L, Miksztowicz V, Buchholz B, Carrión CL, Schreier L, Wikinski R, Gelpi RJ, Berg G, Basso N. J Cardiovasc Pharmacol; 2009 Feb; 53(2):137-44. PubMed ID: 19188835 [Abstract] [Full Text] [Related]
3. Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion. Weinberg EO, Scherrer-Crosbie M, Picard MH, Nasseri BA, MacGillivray C, Gannon J, Lian Q, Bloch KD, Lee RT. Am J Physiol Heart Circ Physiol; 2005 Apr; 288(4):H1802-9. PubMed ID: 15563531 [Abstract] [Full Text] [Related]
4. Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury. Ke D, Fang J, Fan L, Chen Z, Chen L. Coron Artery Dis; 2013 Jun; 24(4):334-41. PubMed ID: 23531479 [Abstract] [Full Text] [Related]
5. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. Jones SP, Gibson MF, Rimmer DM, Gibson TM, Sharp BR, Lefer DJ. J Am Coll Cardiol; 2002 Sep 18; 40(6):1172-8. PubMed ID: 12354446 [Abstract] [Full Text] [Related]
6. Statins and the response to myocardial injury. Scalia R. Am J Cardiovasc Drugs; 2005 Sep 18; 5(3):163-70. PubMed ID: 15901204 [Abstract] [Full Text] [Related]
7. Cardioprotective effects of low-dose combination therapy with rosuvastatin and fasudil in the isolated rat heart. Wu N, Li W, Lv Y, Shu W, Jia D. Pharmazie; 2014 Sep 18; 69(9):704-8. PubMed ID: 25272944 [Abstract] [Full Text] [Related]
8. Long-term administration of rosuvastatin prevents contractile and electrical remodelling of diabetic rat heart. Ozturk N, Yaras N, Ozmen A, Ozdemir S. J Bioenerg Biomembr; 2013 Aug 18; 45(4):343-52. PubMed ID: 23640692 [Abstract] [Full Text] [Related]
10. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Birnbaum Y, Lin Y, Ye Y, Martinez JD, Huang MH, Lui CY, Perez-Polo JR, Uretsky BF. Am J Physiol Heart Circ Physiol; 2007 Jun 18; 292(6):H2891-7. PubMed ID: 17277020 [Abstract] [Full Text] [Related]
11. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. Ikeda Y, Young LH, Lefer AM. J Cardiovasc Pharmacol; 2003 Apr 18; 41(4):649-56. PubMed ID: 12658068 [Abstract] [Full Text] [Related]
12. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M, De Caterina R. Cardiovasc Res; 2005 Jun 01; 66(3):462-71. PubMed ID: 15914111 [Abstract] [Full Text] [Related]
13. Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level. Bulhak AA, Gourine AV, Gonon AT, Sjöquist PO, Valen G, Pernow J. Acta Physiol Scand; 2005 Feb 01; 183(2):151-9. PubMed ID: 15676056 [Abstract] [Full Text] [Related]
15. Effects of rosuvastatin and pitavastatin on ischemia-induced myocardial stunning in dogs. Satoh K, Takaguri A, Itagaki M, Kano S, Ichihara K. J Pharmacol Sci; 2008 Apr 01; 106(4):593-9. PubMed ID: 18403900 [Abstract] [Full Text] [Related]
16. Rosuvastatin changes cytokine expressions in ischemic territory and preserves heart function after acute myocardial infarction in rats. Hu X, Sun A, Xie X, Huang Z, Jia J, Yao R, Ge J. J Cardiovasc Pharmacol Ther; 2013 Mar 01; 18(2):162-76. PubMed ID: 23139358 [Abstract] [Full Text] [Related]
17. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats. Engelhorn T, Doerfler A, Heusch G, Schulz R. Neurosci Lett; 2006 Oct 02; 406(1-2):92-6. PubMed ID: 16901636 [Abstract] [Full Text] [Related]
18. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Habibi J, Whaley-Connell A, Qazi MA, Hayden MR, Cooper SA, Tramontano A, Thyfault J, Stump C, Ferrario C, Muniyappa R, Sowers JR. Endocrinology; 2007 May 02; 148(5):2181-8. PubMed ID: 17317778 [Abstract] [Full Text] [Related]
19. Rosuvastatin reduces rat intestinal ischemia-reperfusion injury associated with the preservation of endothelial nitric oxide synthase protein. Naito Y, Katada K, Takagi T, Tsuboi H, Kuroda M, Handa O, Kokura S, Yoshida N, Ichikawa H, Yoshikawa T. World J Gastroenterol; 2006 Apr 07; 12(13):2024-30. PubMed ID: 16610051 [Abstract] [Full Text] [Related]